OCUL
Price
$12.53
Change
+$0.29 (+2.37%)
Updated
Sep 26 closing price
Capitalization
2.18B
43 days until earnings call
SCPH
Price
$5.65
Change
+$0.04 (+0.71%)
Updated
Sep 26 closing price
Capitalization
303.29M
38 days until earnings call
Interact to see
Advertisement

OCUL vs SCPH

Header iconOCUL vs SCPH Comparison
Open Charts OCUL vs SCPHBanner chart's image
Ocular Therapeutix
Price$12.53
Change+$0.29 (+2.37%)
Volume$1.98M
Capitalization2.18B
scPharmaceuticals
Price$5.65
Change+$0.04 (+0.71%)
Volume$2.76M
Capitalization303.29M
OCUL vs SCPH Comparison Chart in %
Loading...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
OCUL vs. SCPH commentary
Sep 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OCUL is a Buy and SCPH is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 28, 2025
Stock price -- (OCUL: $12.53 vs. SCPH: $5.65)
Brand notoriety: OCUL and SCPH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OCUL: 90% vs. SCPH: 197%
Market capitalization -- OCUL: $2.18B vs. SCPH: $303.29M
OCUL [@Biotechnology] is valued at $2.18B. SCPH’s [@Biotechnology] market capitalization is $303.29M. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OCUL’s FA Score shows that 0 FA rating(s) are green whileSCPH’s FA Score has 0 green FA rating(s).

  • OCUL’s FA Score: 0 green, 5 red.
  • SCPH’s FA Score: 0 green, 5 red.
According to our system of comparison, both OCUL and SCPH are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OCUL’s TA Score shows that 4 TA indicator(s) are bullish while SCPH’s TA Score has 4 bullish TA indicator(s).

  • OCUL’s TA Score: 4 bullish, 5 bearish.
  • SCPH’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, SCPH is a better buy in the short-term than OCUL.

Price Growth

OCUL (@Biotechnology) experienced а +3.55% price change this week, while SCPH (@Biotechnology) price change was +0.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.00%. For the same industry, the average monthly price growth was +9.18%, and the average quarterly price growth was +54.60%.

Reported Earning Dates

OCUL is expected to report earnings on Nov 10, 2025.

SCPH is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+4.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($2.18B) has a higher market cap than SCPH($303M). SCPH YTD gains are higher at: 59.605 vs. OCUL (46.721). SCPH has higher annual earnings (EBITDA): -85.55M vs. OCUL (-200.5M). OCUL has more cash in the bank: 391M vs. SCPH (40.8M). SCPH has less debt than OCUL: SCPH (52.4M) vs OCUL (76.9M). OCUL has higher revenues than SCPH: OCUL (56.7M) vs SCPH (50M).
OCULSCPHOCUL / SCPH
Capitalization2.18B303M719%
EBITDA-200.5M-85.55M234%
Gain YTD46.72159.60578%
P/E RatioN/AN/A-
Revenue56.7M50M113%
Total Cash391M40.8M958%
Total Debt76.9M52.4M147%
FUNDAMENTALS RATINGS
OCUL vs SCPH: Fundamental Ratings
OCUL
SCPH
OUTLOOK RATING
1..100
939
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
60
Fair valued
PROFIT vs RISK RATING
1..100
84100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
4039
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OCUL's Valuation (53) in the Pharmaceuticals Other industry is in the same range as SCPH (60) in the Pharmaceuticals Major industry. This means that OCUL’s stock grew similarly to SCPH’s over the last 12 months.

OCUL's Profit vs Risk Rating (84) in the Pharmaceuticals Other industry is in the same range as SCPH (100) in the Pharmaceuticals Major industry. This means that OCUL’s stock grew similarly to SCPH’s over the last 12 months.

OCUL's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as SCPH (100) in the Pharmaceuticals Major industry. This means that OCUL’s stock grew similarly to SCPH’s over the last 12 months.

SCPH's Price Growth Rating (39) in the Pharmaceuticals Major industry is in the same range as OCUL (40) in the Pharmaceuticals Other industry. This means that SCPH’s stock grew similarly to OCUL’s over the last 12 months.

SCPH's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as OCUL (100) in the Pharmaceuticals Other industry. This means that SCPH’s stock grew similarly to OCUL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
OCULSCPH
RSI
ODDS (%)
Bearish Trend 3 days ago
74%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
71%
Bearish Trend 3 days ago
89%
Momentum
ODDS (%)
Bearish Trend 3 days ago
78%
Bullish Trend 3 days ago
78%
MACD
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 12 days ago
78%
Declines
ODDS (%)
Bearish Trend 12 days ago
85%
Bearish Trend 4 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
89%
Aroon
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MKDVX21.110.21
+1.00%
BlackRock Equity Dividend K
BFGFX51.110.41
+0.80%
Baron Focused Growth Retail
MSMIX31.880.24
+0.76%
NYLI WMC Value Investor Class
AUUIX24.830.10
+0.40%
AB Select US Equity I
SIBAX38.900.12
+0.31%
Sit Balanced

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
+2.37%
EYPT - OCUL
65%
Loosely correlated
+5.38%
IDYA - OCUL
56%
Loosely correlated
+4.44%
NRIX - OCUL
56%
Loosely correlated
+7.20%
IMVT - OCUL
55%
Loosely correlated
+3.57%
CRNX - OCUL
55%
Loosely correlated
+27.92%
More

SCPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, SCPH has been loosely correlated with AUTL. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if SCPH jumps, then AUTL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCPH
1D Price
Change %
SCPH100%
+0.71%
AUTL - SCPH
42%
Loosely correlated
+4.00%
IPSC - SCPH
41%
Loosely correlated
+4.39%
CABA - SCPH
39%
Loosely correlated
+2.16%
OCUL - SCPH
38%
Loosely correlated
+2.37%
ATAI - SCPH
38%
Loosely correlated
+1.93%
More